• Pelthos Therapeutics posted a net loss of USD 10.24 million for the quarter ended March 31, 2026, widening from a net loss of USD 1.97 million a year earlier.
• Revenue was USD 10.91 million, including net product revenues of USD 10.67 million from ZELSUVMI sales.
• Operating loss widened to USD 13.09 million as operating expenses climbed to USD 23.99 million, led by selling, general and administrative costs of USD 21.1 million.
• Cash totaled USD 32 million at quarter-end, following a USD 30 million borrowing under a senior secured term loan facility that totals up to USD 50 million.
• Pipeline update included first patient dosed in Phase 1b/2a trial of CT2000 for eye pain, while XEPI relaunch is expected in early 2027 and XEGLYZE launch is expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pelthos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001919246-26-000070), on May 14, 2026, and is solely responsible for the information contained therein.